高危急性髓系白血病儿童单倍体造血干细胞移植的长期随访:单中心报告
分析本中心2015年至2021年间首次接受单倍体造血干细胞移植的200例高危急性髓系白血病患儿。4年总生存率71.9%、无事件生存率62.3%、累积复发率32.4%。移植前微小残留病阳性与更低的生存和更高的复发风险显著相关;非唐氏综合征急性巨核细胞白血病预后极差,亟需联合新疗法。
要点
- 移植前微小残留病阳性者4年总生存率63.4%,阴性者80.5%。
- 非唐氏综合征急性巨核细胞白血病患者即使接受单倍体移植,预后仍极差。
- 4年累积复发率32.4%,100天III-IV度急性移植物抗宿主病累积发生率9.5%。
核心结论
- 单倍体造血干细胞移植可作为这类患者的治疗选择,移植前微小残留病状态显著影响结局。
- 非唐氏综合征急性巨核细胞白血病患者即使接受单倍体移植预后仍极差,亟需联合新疗法。
研究设计与样本
- 回顾性分析本中心2015年至2021年间首次接受单倍体造血干细胞移植的200例高危急性髓系白血病患儿。
- 原文未报告局限性。
主要发现
- 4年总生存率、无事件生存率和累积复发率分别为71.9%、62.3%和32.4%。
- 100天II-IV度和III-IV度急性移植物抗宿主病累积发生率分别为41.1%和9.5%。
- 4年慢性移植物抗宿主病累积发生率为56.1%,中重度慢性移植物抗宿主病为27.3%。
- 移植前微小残留病阳性组(n=97)4年总生存率63.4%、无事件生存率51.4%、累积复发率41.0%,阴性组(n=103)分别为80.5%、73.3%、23.8%。
- 多因素分析显示非唐氏综合征急性巨核细胞白血病与极差结局相关:总生存风险比3.110(95%CI 1.430-6.763,P=0.004),无事件生存风险比3.145(95%CI 1.628-6.074,P=0.001),累积复发风险比3.250(95%CI 1.529-6.910,P=0.002)。
关键数值与推荐
- 移植前微小残留病状态:阳性组(n=97)4年总生存率63.4%、无事件生存率51.4%、累积复发率41.0%;阴性组(n=103)分别为80.5%、73.3%、23.8%。
- 非唐氏综合征急性巨核细胞白血病:总生存风险比3.110(95%CI 1.430-6.763,P=0.004),无事件生存风险比3.145(95%CI 1.628-6.074,P=0.001),累积复发风险比3.250(95%CI 1.529-6.910,P=0.002)。
临床怎么用
- 作者认为单倍体造血干细胞移植可作为这类患者的治疗选择。
- 作者指出非唐氏综合征急性巨核细胞白血病患者即使接受单倍体移植预后仍极差,亟需联合新疗法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data from 200 children with high-risk acute myeloid leukaemia who underwent their first haploidentical haematopoietic stem cell transplantation (haplo-HSCT) between 2015 and 2021 at our institution were analysed. The 4-year overall survival (OS), event-free survival (EFS) and cumulative incidence of relapse (CIR) were 71.9%, 62.3% and 32.4% respectively. The 100-day cumulative incidences of grade II-IV and III-IV acute graft-versus-host disease (aGVHD) were 41.1% and 9.5% respectively. The 4-year cumulative incidence of chronic GVHD (cGVHD) was 56.1%, and that of moderate-to-severe cGVHD was 27.3%. Minimal residual disease (MRD)-positive (MRD+) status pre-HSCT was significantly associated with lower survival and a higher risk of relapse. The 4-year OS, EFS and CIR differed significantly between patients with MRD+ pre-HSCT (n = 97; 63.4%, 51.4% and 41.0% respectively) and those with MRD-negative (MRD-) pre-HSCT (n = 103; 80.5%, 73.3% and 23.8% respectively). Multivariate analysis also revealed that acute megakaryoblastic leukaemia without Down syndrome (non-DS-AMKL) was associated with extremely poor outcomes (hazard ratios and 95% CIs for OS, EFS and CIR: 3.110 (1.430-6.763), 3.145 (1.628-6.074) and 3.250 (1.529-6.910) respectively; p-values were 0.004, 0.001 and 0.002 respectively). Thus, haplo-HSCT can be a therapy option for these patients, and MRD status pre-HSCT significantly affects the outcomes. As patients with non-DS-AMKL have extremely poor outcomes, even with haplo-HSCT, a combination of novel therapies is urgently needed.
引用
- Bai L, Zhang ZX, Hu GH, et al. Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre. Br J Haematol. 2023. PMID: 37658699. doi:10.1111/bjh.19086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。